Cite
HARVARD Citation
Fathi, A. et al. (2018). Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 124 (2), pp. 306-314. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Fathi, A. et al. (2018). Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 124 (2), pp. 306-314. [Online].